Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years. There have been no capital gains, and the dividend yield is mediocre at best. This has forced Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)to undertake a radical overhaul of its business strategy.

The recently-released second quarter results did not reflect the effects of this improved business strategy. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) barely managed to meet expectations, with margins and revenues below expectations.

However, there are indications that it will start reaping the benefits of an improved business strategy by the end of this year. The rewards from NTE focus and recent acquisitions can improve valuations

New Strategy

The company has decided to strive for growth rather than focus on returning shareholder value. The company will limit its branded segment to CNS and Respiratory. It is also trying to acquire promising candidates in these segments and find more applications of existing molecules.

In the last few quarters, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has emerged as a major player in OTC due to its partnership with P&G. It already has more than $600 million in OTC sales, and expects to cross the $1 billion mark by next year. The global consumer healthcare industry is approximately a $200 billion industry, and is expected to grow by more than 10% in coming years. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s presence in OTC will ensure diversified revenues, reducing the threat of a single drug’s patent expiry.

The most intriguing part of this new strategy by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is its increased focus on NTEs (New Therapeutic Entities). The company plans to discover novel uses of molecules already in its current portfolio, including molecules in both its generic and its branded pipeline. Teva will focus on novel applications of these molecules and formulating innovative combinations. The beauty of this strategy lies in its cost effectiveness. As the world’s leader in generic drugs, Teva has hundreds of compounds in its pipeline. This will allow it to find new products without any further expenses on R&D or extensive clinical trials. Clinical trials would still be required, but they are usually less lengthy and costly for already-approved compounds.

Acquisitions

In the recent past, the company has made a number of interesting acquisitions. Last month it acquired MicroDoseTherapeutx for $165 million, which includes $125 million in terms of milestone payments and royalties. Microdose is involved in developing treatments to prevent viral respiratory infections. This acquisition will give Teva MDT-637, a treatment for respiratory syncytial virus.

Teva has also completed the acquisition of Taiyo Pharmaceuticals for a whopping $943 million in cash. This acquisition will allow Teva to enter the highly lucrative Japanese generics market. Japan is the second largest pharmaceutical market in the world, valued at $96 billion, with a low generic penetration hovering around the 25% mark. The government is trying to increase this percentage to around 30%. Taiyo’s 550 product portfolio will allow Teva to establish a dominant presence in the growing Japanese generics market.